Bacterial Vaginosis Pipeline H2 2016 Market Research Report

Aug 18, 2016, 04:00 ET from RnR Market Research

PUNE, India, August 18, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Bacterial Vaginosis - Pipeline Review, H2 2016" market research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.

The report also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H2 2016 pipeline review of Bacterial Vaginosis with 22 market data tables and 11 figures, spread across 61 pages is available at http://www.rnrmarketresearch.com/bacterial-vaginosis-pipeline-review-h2-2016-market-report.html .

Bacterial Vaginosis Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.  

Bacterial Vaginosis pipeline therapeutics constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Companies discussed in this Bacterial Vaginosis Pipeline Review, H1 2016 report include Alfa Wassermann S.p.A, AmVac AG (Inactive), Evofem, Inc., Osel, Inc., Starpharma Holdings Limited and Symbiomix Therapeutics, LLC. Drug Profile mentioned in this research are Amphora, AMV-100, astodrimer, benzoyl peroxide, LACTIN-V, rifaximin, secnidazole, Small Molecule for Bacterial Vaginosis and Candidiasis, subtilosin and TOL-463.

Order a copy of H2 2016 bacterial vaginosis pipeline market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=662433 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis and reviews pipeline therapeutics for Bacterial Vaginosis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Bacterial Vaginosis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Bacterial Vaginosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Bacterial Vaginosis.

Another newly published market research report titled on Down Syndrome - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Down Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Down Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are AC Immune SA, Aelis Farma SAS, Cortice Biosciences, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., NeuroNascent, Inc. and Transition Therapeutics Inc. Down Syndrome Pipeline market research report of 69 pages is available at http://www.rnrmarketresearch.com/down-syndrome-pipeline-review-h2-2016-market-report.html .

Explore more reports on Therapeutics.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research